On July 3, the Colorado Prescription Drug Affordability Board (PDAB or Board) voted to initiate the upper payment limit (UPL) rulemaking process for two more drugs, Stelara and Cosentyx, after deeming them “unaffordable for Colorado consumers” in June.
In advance of the July 3 PDAB meeting, CBSA and BIO submitted a joint comment letter urging the PDAB to carefully consider how it acts on the directive to consider setting UPLs and imploring the PDAB to tread carefully to ensure Colorado does not harm patients in its quest to be the first in the nation to implement this experimental program.
Amy Goodman, CBSA’s Vice President and Counsel for Policy + Advocacy, also provided public comment during the July 3 PDAB meeting, reminding the PDAB that they have the power—and the responsibility—to determine whether setting a UPL would actually accomplish the goals of helping…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
